FK778

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Kidney Transplantation

Conditions

Kidney Transplantation

Trial Timeline

Nov 1, 2003 → Oct 1, 2005

NCT ID

NCT00282230

About FK778

FK778 is a phase 2 stage product being developed by Astellas Pharma for Kidney Transplantation. The current trial status is terminated. This product is registered under clinical trial identifier NCT00282230. Target conditions include Kidney Transplantation.

What happened to similar drugs?

20 of 20 similar drugs in Kidney Transplantation were approved

Approved (20) Terminated (1) Active (0)

✅Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mgYuhanApproved

✅TacrolimusAstellas PharmaApproved

✅basiliximab + rabbit anti-thymocyte globulin + tacrolimus + alemtuzumab + mycophenolate mofetil + steroidsAstellas PharmaApproved

✅Tacrolimus granulesAstellas PharmaApproved

✅Tacrolimus immediate-release formulation + Tacrolimus prolonged-release formulation + Induction therapy + Mycophenolic acid drugs + CorticosteroidsAstellas PharmaApproved

✅MMF (Cellcept) and Steroids + Tacrolimus (Prograf)Astellas PharmaApproved

✅Advagraf + Mycophenolate Mofetil + Simulect + CorticosteroidsAstellas PharmaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00104338	Phase 2	Terminated	Jan 1, 2005	Aug 1, 2006	BK Polyomavirus
NCT00282230	Phase 2	Terminated	Nov 1, 2003	Oct 1, 2005	Kidney Transplantation
NCT00189735	Phase 2	Completed	Sep 1, 2003	Oct 1, 2005	Kidney Transplantation
NCT00451932	Phase 2	Completed	Oct 1, 2002	Sep 1, 2005	Liver Transplantation

Competing Products

20 competing products in Kidney Transplantation

See all competitors

Product	Company	Stage	Hype Score
Empagliflozin + Matching placebo	Eli Lilly	Phase 3	40
Baricitinib + Placebo	Eli Lilly	Phase 2	35
SGLT2 inhibitor	Eli Lilly	Pre-clinical	30
LY2623091 + Eplerenone	Eli Lilly	Phase 2	35
Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mg	Yuhan	Approved	39
Tacrolimus	Astellas Pharma	Approved	35
Rituximab	Astellas Pharma	Phase 2	35
Prograf + MR4	Astellas Pharma	Phase 3	40
basiliximab + rabbit anti-thymocyte globulin + tacrolimus + alemtuzumab + mycophenolate mofetil + steroids	Astellas Pharma	Approved	43
Tacrolimus, modified release	Astellas Pharma	Phase 3	40
Tacrolimus granules	Astellas Pharma	Approved	43
roxadustat	Astellas Pharma	Phase 3	40
Tacrolimus immediate-release formulation + Tacrolimus prolonged-release formulation + Induction therapy + Mycophenolic acid drugs + Corticosteroids	Astellas Pharma	Approved	43
ASP1128 + Placebo	Astellas Pharma	Phase 2	35
FK506MR + Prograf + Mycophenolate Mofetil + Methylprednisolone + Prednisolone	Astellas Pharma	Phase 3	40
MMF (Cellcept) and Steroids + Tacrolimus (Prograf)	Astellas Pharma	Approved	43
ASP1585	Astellas Pharma	Phase 3	40
Alefacept + tacrolimus + basiliximab + mycophenolate mofetil + Corticosteroids	Astellas Pharma	Phase 2	35
Advagraf + Mycophenolate Mofetil + Simulect + Corticosteroids	Astellas Pharma	Approved	43
tacrolimus	Astellas Pharma	Approved	39